<DOC>
	<DOCNO>NCT00174811</DOCNO>
	<brief_summary>The clinical activity telithromycin vs. cefuroxime child acute infection middle ear , age 6 month 59 month old study .</brief_summary>
	<brief_title>Comparative Study Evaluate Efficacy Safety Telithromycin Given Once Daily Versus Cefuroxime Axetil Given Twice Daily Children With Middle Ear Infections</brief_title>
	<detailed_description />
	<mesh_term>Otitis</mesh_term>
	<mesh_term>Otitis Media</mesh_term>
	<mesh_term>Telithromycin</mesh_term>
	<mesh_term>Cefuroxime axetil</mesh_term>
	<mesh_term>Cefuroxime</mesh_term>
	<criteria>Subjects ≥6 month &lt; 59 month age AOM ; Recent ( within last 72 hour ) rapid onset AOM sign symptom ; The presence MEF otoscopy indicate bulge tympanic membrane ; Otalgia ear tug touch within last 24 hour interfere precludes normal activity sleep ; At least 1 follow clinical finding specific AOM : fever , vomit , diarrhea , anorexia , sleep disturbance , irritability ; Tympanocentesis perform per protocol MEF sample collect ; Informed consent must obtain write enrollment study , child 's parent/legally authorize representative . The parent/legally authorized representative agree provide followup information arrange schedule visit , even event study medication discontinue . Uncertain diagnosis AOM sign symptom AOM would make subject candidate observation analgesic therapy observation 23 day ; Otorrhea tympanostomy tube present either ear study entry ; Otitis externa ; Down syndrome , cleft palate , craniofacial disorder , cystic fibrosis/mucoviscidosis , immotile cilium syndrome , congenital immunodeficiency acquire immunodeficiency syndrome &lt; 25 % CD4 count require prophylaxis Pneumocystis jiroveci ( carinii ) require treatment opportunistic infection ; Known congenital prolong QT syndrome ; Uncorrected hypokalemia ( ≤3 mmol/L [ mEq/L ] ) , hypomagnesemia ( base laboratory assessment ) , bradycardia ( &lt; 50 bpm ) ; Myasthenia gravis ; Known impair renal function , show creatinine clearance ≤25 mL/min ; Any medical condition ( include developmental disorder , visual disorder , ocular abnormality ) , opinion investigator , would interfere implementation protocol interpretation study result ; The subject : Is treat drug permit study protocol ie , cisapride , pimozide , astemizole , terfenadine , ergotamine , dihydroergotamine , class IA ( eg , quinidine procainamide ) Class III ( eg , dofetilide ) antiarrhythmic agent , simvastatin , lovastatin atorvastatin ; Is currently treat systemic antibacterial treat systemic antibacterial within 5 day prior enrollment ; Has treat investigational medication within last 30 day ; Has treat rifampicin , phenytoin , carbamazepine , St. John 's wort within last 2 week . History hypersensitivity intolerance macrolides , penicillin , cephalosporin ; Previous enrollment study previous treatment telithromycin ; Children investigator subinvestigator , research assistant , pharmacist , study coordinator , staff , relative thereof directly involve conduct protocol .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>59 Months</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>acute otitis medium</keyword>
	<keyword>control clinical trial</keyword>
	<keyword>telithromycin</keyword>
	<keyword>cefuroxime axetil</keyword>
	<keyword>middle ear infection</keyword>
	<keyword>tympanocentecis</keyword>
</DOC>